Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene mutations are frequent drivers in non-small cell lung cancer (NSCLC).
• Despite high prevalence, effective treatments for KRAS-mutated NSCLC remain limited due to pathway complexity.
• Targeted therapies have shown success for KRAS p.G12C mutations, but other KRAS alterations require further investigation.

Purpose of the Study:

• To provide a comprehensive overview of current research on non-p.G12C KRAS mutations in NSCLC.
• To critically evaluate ongoing therapeutic strategies for these patient populations.
• To discuss future directions and potential treatment advancements.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of ongoing clinical trials for KRAS-mutated NSCLC.
• Discussion of mutation subtypes, co-mutations, and downstream signaling pathways.

Main Results:

• While KRAS p.G12C targeted therapies show promise, the treatment landscape for other KRAS mutations is evolving.
• Several promising therapeutic strategies are emerging for various KRAS mutation subtypes.
• Understanding mutation complexity is key to developing effective treatments.

Conclusions:

• The treatment landscape for non-p.G12C KRAS-mutated NSCLC is poised for significant change.
• Further research into targeted therapies and combination strategies is crucial.
• Future scenarios offer hope for improved outcomes in this challenging NSCLC subgroup.